Jiang Y, Ji L. Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
J Int Med Res 2020;
48:300060520959487. [PMID:
32993392 PMCID:
PMC7536494 DOI:
10.1177/0300060520959487]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
A 55-year-old woman developed acute promyelocytic leukaemia during treatment with
all-trans-retinoic acid and arsenic trioxide. Initially, she presented with symptoms of
epigastric pain, vomiting, and nausea, and she developed acute pancreatitis. She was
treated with parenteral nutritional supplementation for 20 days. However, the patient
continued to develop refractory hyponatraemia, hypotension, and apathy. Finally, the
patient was diagnosed with Wernicke encephalopathy (WE) using head magnetic resonance
imaging. The patient underwent high-dose intravenous thiamine administration, and her
symptoms were alleviated. WE is a rare adverse event during acute pancreatitis therapy.
Acute pancreatitis that is caused by all-trans-retinoic acid and arsenic trioxide is a
rare complication of acute promyelocytic leukaemia during chemotherapy. Further study is
essential to improve our comprehension of the risk factors for complications in patients
with acute promyelocytic leukaemia, considering that the associated complications were
potentially caused by multiple etiological factors. A better understanding of these risk
factors may help to improve the prognosis of patients with acute promyelocytic leukaemia
at an early stage.
Collapse